AZD9291 (osimertinib)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for AZD9291 (osimertinib), covering 2016-07-14 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer [Phase 1]